Statins, cholesterol, Co-enzyme Q10, and Parkinson's disease

Abraham Lieberman, Kelly Lyons, Jay Levine, Robert J Myerburg

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

'Statins', drugs that lower cholesterol are widely used. Statins block cholesterol in the body and brain by inhibiting HMG-Co-A reductase. This pathway is shared by CoQ-10. An unintended consequence of the statins is lowering of CoQ-10. As CoQ-10 may play a role in PD, its possible statins may worsen PD. Such a report has appeared. Statins came into wide use in 1997-1998, 6 years before our study began. Thus 74% of our patients on a statin had a PD duration of 1-6 years versus 56% of our patients not on a statin. A direct comparison of patients on a statin and not on a statin would bias the study in favor of the statins: patients on a statin would have a shorter disease duration and less advanced PD. Therefore we divided the patients into two groups. Group I consisted of 128 patients on a statin, and 252 not on a statin who had PD for 1-6 years. In this group, disease severity (Hoehn & Yahr Stage), levodopa dose, Co-enzyme Q10 use, prevalence of 'wearing off', dyskinesia and dementia were similar. Group II consisted of 45 patients on a statin and 200 patients not on a statin who had PD for 7-22 years. In this group disease severity, levodopa dose, Co-enzyme Q10 use, prevalence of wearing off, dyskinesia and dementia were similar. Statins although they may affect Co-enzyme Q10 levels in the body and the brain, do not worsen PD at least as assessed by stage, and prevalence of wearing-off, dyskinesia, and dementia.

Original languageEnglish
Pages (from-to)81-84
Number of pages4
JournalParkinsonism and Related Disorders
Volume11
Issue number2
DOIs
StatePublished - Mar 1 2005

Fingerprint

coenzyme Q10
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Parkinson Disease
Cholesterol
Dyskinesias
Dementia
Levodopa

Keywords

  • Coenzyme Q-10
  • Parkinson's disease
  • Statins

ASJC Scopus subject areas

  • Aging
  • Clinical Neurology
  • Neurology

Cite this

Statins, cholesterol, Co-enzyme Q10, and Parkinson's disease. / Lieberman, Abraham; Lyons, Kelly; Levine, Jay; Myerburg, Robert J.

In: Parkinsonism and Related Disorders, Vol. 11, No. 2, 01.03.2005, p. 81-84.

Research output: Contribution to journalArticle

Lieberman, Abraham ; Lyons, Kelly ; Levine, Jay ; Myerburg, Robert J. / Statins, cholesterol, Co-enzyme Q10, and Parkinson's disease. In: Parkinsonism and Related Disorders. 2005 ; Vol. 11, No. 2. pp. 81-84.
@article{7986941e7ca34867b84551076db04dbf,
title = "Statins, cholesterol, Co-enzyme Q10, and Parkinson's disease",
abstract = "'Statins', drugs that lower cholesterol are widely used. Statins block cholesterol in the body and brain by inhibiting HMG-Co-A reductase. This pathway is shared by CoQ-10. An unintended consequence of the statins is lowering of CoQ-10. As CoQ-10 may play a role in PD, its possible statins may worsen PD. Such a report has appeared. Statins came into wide use in 1997-1998, 6 years before our study began. Thus 74{\%} of our patients on a statin had a PD duration of 1-6 years versus 56{\%} of our patients not on a statin. A direct comparison of patients on a statin and not on a statin would bias the study in favor of the statins: patients on a statin would have a shorter disease duration and less advanced PD. Therefore we divided the patients into two groups. Group I consisted of 128 patients on a statin, and 252 not on a statin who had PD for 1-6 years. In this group, disease severity (Hoehn & Yahr Stage), levodopa dose, Co-enzyme Q10 use, prevalence of 'wearing off', dyskinesia and dementia were similar. Group II consisted of 45 patients on a statin and 200 patients not on a statin who had PD for 7-22 years. In this group disease severity, levodopa dose, Co-enzyme Q10 use, prevalence of wearing off, dyskinesia and dementia were similar. Statins although they may affect Co-enzyme Q10 levels in the body and the brain, do not worsen PD at least as assessed by stage, and prevalence of wearing-off, dyskinesia, and dementia.",
keywords = "Coenzyme Q-10, Parkinson's disease, Statins",
author = "Abraham Lieberman and Kelly Lyons and Jay Levine and Myerburg, {Robert J}",
year = "2005",
month = "3",
day = "1",
doi = "10.1016/j.parkreldis.2004.07.012",
language = "English",
volume = "11",
pages = "81--84",
journal = "Parkinsonism and Related Disorders",
issn = "1353-8020",
publisher = "Elsevier BV",
number = "2",

}

TY - JOUR

T1 - Statins, cholesterol, Co-enzyme Q10, and Parkinson's disease

AU - Lieberman, Abraham

AU - Lyons, Kelly

AU - Levine, Jay

AU - Myerburg, Robert J

PY - 2005/3/1

Y1 - 2005/3/1

N2 - 'Statins', drugs that lower cholesterol are widely used. Statins block cholesterol in the body and brain by inhibiting HMG-Co-A reductase. This pathway is shared by CoQ-10. An unintended consequence of the statins is lowering of CoQ-10. As CoQ-10 may play a role in PD, its possible statins may worsen PD. Such a report has appeared. Statins came into wide use in 1997-1998, 6 years before our study began. Thus 74% of our patients on a statin had a PD duration of 1-6 years versus 56% of our patients not on a statin. A direct comparison of patients on a statin and not on a statin would bias the study in favor of the statins: patients on a statin would have a shorter disease duration and less advanced PD. Therefore we divided the patients into two groups. Group I consisted of 128 patients on a statin, and 252 not on a statin who had PD for 1-6 years. In this group, disease severity (Hoehn & Yahr Stage), levodopa dose, Co-enzyme Q10 use, prevalence of 'wearing off', dyskinesia and dementia were similar. Group II consisted of 45 patients on a statin and 200 patients not on a statin who had PD for 7-22 years. In this group disease severity, levodopa dose, Co-enzyme Q10 use, prevalence of wearing off, dyskinesia and dementia were similar. Statins although they may affect Co-enzyme Q10 levels in the body and the brain, do not worsen PD at least as assessed by stage, and prevalence of wearing-off, dyskinesia, and dementia.

AB - 'Statins', drugs that lower cholesterol are widely used. Statins block cholesterol in the body and brain by inhibiting HMG-Co-A reductase. This pathway is shared by CoQ-10. An unintended consequence of the statins is lowering of CoQ-10. As CoQ-10 may play a role in PD, its possible statins may worsen PD. Such a report has appeared. Statins came into wide use in 1997-1998, 6 years before our study began. Thus 74% of our patients on a statin had a PD duration of 1-6 years versus 56% of our patients not on a statin. A direct comparison of patients on a statin and not on a statin would bias the study in favor of the statins: patients on a statin would have a shorter disease duration and less advanced PD. Therefore we divided the patients into two groups. Group I consisted of 128 patients on a statin, and 252 not on a statin who had PD for 1-6 years. In this group, disease severity (Hoehn & Yahr Stage), levodopa dose, Co-enzyme Q10 use, prevalence of 'wearing off', dyskinesia and dementia were similar. Group II consisted of 45 patients on a statin and 200 patients not on a statin who had PD for 7-22 years. In this group disease severity, levodopa dose, Co-enzyme Q10 use, prevalence of wearing off, dyskinesia and dementia were similar. Statins although they may affect Co-enzyme Q10 levels in the body and the brain, do not worsen PD at least as assessed by stage, and prevalence of wearing-off, dyskinesia, and dementia.

KW - Coenzyme Q-10

KW - Parkinson's disease

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=14044257335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14044257335&partnerID=8YFLogxK

U2 - 10.1016/j.parkreldis.2004.07.012

DO - 10.1016/j.parkreldis.2004.07.012

M3 - Article

C2 - 15734664

AN - SCOPUS:14044257335

VL - 11

SP - 81

EP - 84

JO - Parkinsonism and Related Disorders

JF - Parkinsonism and Related Disorders

SN - 1353-8020

IS - 2

ER -